Skip to main content
logo
Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
25.06
+2.05 (8.91%)
At close: Aug 4, 2026, 4:00 PM EDT
25.15
+0.09 (0.36%)
Pre-market: Aug 5, 2026, 7:28 AM EDT

Immunome Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4.026.949.0414.02--
Revenue Growth
-63.29%-23.23%-35.50%---
Gross Profit
4.026.949.0414.02--
Operating Income
-238.81-224.11-305.8-109.53-36.9-25.2
Net Income
-224.59-212.39-292.96-106.81-37.52-24.71
Earnings Per Share
-2.38-2.43-5.00-5.38-3.09-2.14
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
582.69653.48217.3138.1420.3249.23
Total Debt
3.693.864.771.3400
Net Cash (Debt)
579649.63212.53136.820.3249.23
Net Cash Growth
85.25%205.66%55.36%573.14%-58.72%25.76%
Net Cash Per Share
6.057.443.626.891.684.27

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-196.5-190.92-110.79-7.57-28.69-18.23
Capital Expenditures
-9.02-9.69-7.17-0.83-0.25-0.08
Free Cash Flow
-205.52-200.6-117.97-8.4-28.94-18.31
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-5947.90%-3228.83%-3382.37%-781.35%--
Pretax Margin
-5593.85%-3059.99%-3240.38%-761.92%--
Profit Margin
-5593.85%-3059.99%-3240.38%-761.92%--
FCF Margin
-5118.90%-2890.13%-1304.80%-59.92%--

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
706.86350.1175.7233.01--